ChromaDex (CDXC) Lowered to Sell at ValuEngine
ValuEngine downgraded shares of ChromaDex (NASDAQ:CDXC) from a hold rating to a sell rating in a report released on Friday morning.
Several other research analysts also recently commented on CDXC. HC Wainwright set a $5.00 target price on ChromaDex and gave the stock a buy rating in a report on Friday, August 11th. Zacks Investment Research downgraded ChromaDex from a hold rating to a strong sell rating in a report on Tuesday, August 15th. Finally, Ladenburg Thalmann Financial Services started coverage on ChromaDex in a report on Monday, September 25th. They set a buy rating and a $7.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $7.13.
Shares of ChromaDex (NASDAQ:CDXC) traded down $0.33 on Friday, hitting $6.59. The stock had a trading volume of 660,139 shares, compared to its average volume of 444,348. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.12 and a current ratio of 5.03. ChromaDex has a fifty-two week low of $2.25 and a fifty-two week high of $7.24.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Thompson Davis & CO. Inc. bought a new stake in shares of ChromaDex in the 3rd quarter valued at $128,000. Bank of Montreal Can bought a new position in ChromaDex during the 2nd quarter worth about $168,000. LMR Partners LLP bought a new position in ChromaDex during the 2nd quarter worth about $347,000. Goldman Sachs Group Inc. increased its holdings in ChromaDex by 870.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after purchasing an additional 163,817 shares in the last quarter. Finally, Granite Investment Partners LLC increased its holdings in ChromaDex by 5.7% during the 3rd quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after purchasing an additional 13,599 shares in the last quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “ChromaDex (CDXC) Lowered to Sell at ValuEngine” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/02/chromadex-cdxc-lowered-to-sell-at-valuengine.html.
ChromaDex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Stock Ratings for ChromaDex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Corporation and related stocks with our FREE daily email newsletter.